VILTEPSO® (viltolarsen) injection Open Label Extension Clinical Trial Data Scheduled for Presentation at the MDA Clinical & Scientific Conference 2023 ...Middle East

PR Newswire - News
Data were from a final four-year analysis (up to Week 216) of the open-label extension trial of a VILTEPSO Phase 2 study NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), is a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Dr. Toru Nakai) PARAMUS, N....

Hence then, the article about viltepso viltolarsen injection open label extension clinical trial data scheduled for presentation at the mda clinical scientific conference 2023 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( VILTEPSO® (viltolarsen) injection Open Label Extension Clinical Trial Data Scheduled for Presentation at the MDA Clinical & Scientific Conference 2023 )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News